Oxford Medical Simulation (OMS) secures £5m to expand US AI clinical training
This article covers Oxford Medical Simulation, a healthtech startup, which has secured £5m in venture debt to accelerate the roll-out of its immersive clinical training platform. The financing is intended to speed US health-system and academic adoption and to fund product work such as AI-driven scenarios, learning analytics and workflow tools, supporting clinician training and addressing workforce pressures and clinical readiness.
Oxford Medical Simulation, a healthtech startup, has secured £5 million in Venture Debt to accelerate the roll-out of its immersive clinical training platform. The financing is intended to speed US health system and academic adoption and fund product work such as AI-driven scenarios, learning analytics and workflow tools — capabilities that aim to address workforce pressures and clinical readiness.
Why it matters
Healthcare providers face persistent staffing gaps and the need to onboard and upskill clinicians faster and more consistently. Digital simulation tools promise repeatable, measurable training that can be delivered without taking patients or instructors out of clinical service. For institutions balancing budgets and outcomes, a £5 million injection aimed at scaling deployments and analytics could influence how widely simulation is adopted across training pipelines and continuing professional development.
Inside the product
OMS delivers immersive, simulated clinical scenarios that users can practise on demand. The company combines scenario authoring, AI-driven case logic and learning analytics to track performance and identify recurring gaps. That mix is intended to let educators standardise training, measure competence, and integrate simulated practice into workflows rather than treating it as a standalone exercise.
The firm says it works with hospitals, health systems and universities across the US, UK and internationally. Key product development priorities named in the announcement include expanding clinical content, deepening analytics capabilities and building infrastructure to support larger institutional customers.
Who are the investors?
The financing comes from Salica Investments, a UK-based investment firm that manages a suite of private market funds investing in equity and debt across predominantly UK businesses. Salica provided the venture debt facility to support OMS’ US expansion, product innovation and operational scaling.
In the announcement, Usman Ali, Partner at one of the funds at Salica, said:
Oxford Medical Simulation is exactly the type of business we look to support. The team has built a differentiated platform, proven at scale, and is working with leading health systems and universities to address a critical need: giving clinicians and students the chance to practise safely. We are delighted to back OMS as they scale their impact across healthcare and education.
If you're researching potential backers in this space:
- Explore our list of healthtech venture capital firms in the UK
- Browse our directory of healthtech angel investors in the UK
Founder perspective
OMS was founded almost a decade ago by clinicians who identified gaps between education and on-the-job performance. The company has positioned its product as a bridge between classroom learning and clinical practice, with particular emphasis on repeatable, outcomes-focused scenarios.
In the announcement, Michael Wallace, CEO of Oxford Medical Simulation, said:
This financing allows us to invest confidently in the next phase of OMS. Our partners in US healthcare and academia are focused on outcomes – safer practice, better-prepared staff and more efficient delivery. This growth capital from Salica means we can move faster on exactly those priorities: expanding our breadth and depth of content, deepening our analytics capabilities, and supporting more institutions to transform their training for the new generation of learners.
The bigger picture
The deal highlights two intersecting trends in healthtech financing. First, digital clinical training vendors are moving beyond pilot projects toward enterprise deployments with measurable performance metrics. Second, venture debt is becoming a more common tool for companies that need capital to scale infrastructure and customer success functions without diluting equity further.
For healthcare providers, the test will be whether simulation platforms can demonstrate improvements in real-world outcomes, such as reduced error rates or faster time-to-competence for new staff. For investors and procurement teams, measurable analytics and integration into existing workflows will be key criteria.
This transaction also underlines continued interest from healthtech investors in solutions that address workforce and training pressures across the UK, US and Europe. As UK startups seek transatlantic growth, financing structures that support scaling rather than just product development will shape which companies can move from pilots to system-wide adoption.
They've invested in Oxford Medical Simulation (OMS)
Get to know these healthtech investors
Click here for a full list of 7,526+ startup investors in the UK